Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Biotechnology

Healthcare
$2.75 +1.73%

+$0.14 today

Market cap
$56.57M
Beta
2.59
P/E (TTM)
-1.3
EPS (TTM)
-$6.35
52W Low $6.72High $20.56

Volume 0.63M

Average 0.42M

CRBP Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Corbus Pharmaceuticals Holdings, Inc.NASDAQ: CRBP

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $19.82M rose 26.7% year over year, behind the +76.4% change in trailing-twelve-month research & development. Sequentially, it rose 7.7% from the prior quarter. Over 3 fiscal years it compounded at +63.2% a year.

Context

  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +26.7% toward the trailing-twelve-month pace of +76.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.82M+7.7% QoQ
Last fiscal yearDec 2025
$70.1M+117.5% YoY
LTMMar 2026
$74.27M+76.4% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+26.7%——
1 year+117.5%——
3-year CAGR+63.2%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
70.1M USD
Year-over-year change
+117.5%
4-year CAGR
+17.8%

Research & Development vs competitors

How CRBP compares with its peers on the latest reported figures

  • Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +76.4% is the 2nd highest of 10, against a peer median of -19.6%.
  • Over three fiscal years its annual growth of +63.2% compares with a peer median of -5.5%.
CRBP Competitors
Research & Development for CRBP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$114.68M USD-37.7%-16.4%622.7%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$74.27M USD+76.4%+63.2%—
FBRXForte Biosciences, Inc.LTM Mar 2026$65.43M USD+123.8%+118.4%—
PEPGPepGen Inc.LTM Mar 2026$58.35M USD-32.7%+9.5%—
MOLNMolecular Partners AGLTM Mar 2026CHF 46.97M CHF-1.7%-7.5%—
IPHAInnate Pharma S.A.FY2025€43.62M EUR-16.1%-5.5%1565.1%
CRDFCardiff Oncology, Inc.LTM Mar 2026$31.62M USD-19.6%+9.2%6022.3%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$23.84M USD-29.5%+13.5%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$18.8M USD-26.8%-18.0%593.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$16.56M USD+5.5%-23.1%928.4%
Peer median (excluding CRBP) —-19.6%-5.5%928.4%

Competitors are the stored peer set for CRBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue881.71K0000
Cost of Revenue1.64M1.49M0600K0
Gross Profit(757.53K)(1.49M)0(600K)0
Gross Margin-85.9%————
Research & Development36.45M16.14M31.17M32.22M70.1M
Selling, General & Admin20.43M18.7M13.91M16.5M15.22M
Operating Expenses55.23M33.35M45.08M48.12M85.31M
Depreciation & Amortization1.64M1.49M641K600K233K
EBITDA(42.17M)(38.73M)(40.11M)(37.74M)(78.3M)
EBITDA Margin-4782.9%————
Operating Income(55.99M)(34.84M)(45.08M)(48.72M)(85.31M)
Operating Margin-6350.1%————
Interest Income0006.31M5.53M
Interest Expense1.83M2.13M2.92M1.87M0
Other Income / Expenses10.35M(7.51M)474K8.51M6.77M
Income Before Tax(45.64M)(42.35M)(44.6M)(40.21M)(78.54M)
Pre-Tax Margin-5176.4%————
Income Tax Expense00000
Net Income(45.55M)(55.83M)(44.6M)(40.21M)(78.54M)
Net Margin-5166.4%————
EPS (Basic)(11.13)(10.15)(10.31)(3.68)(5.90)
EPS (Diluted)(11.13)(10.15)(10.31)(3.68)(5.90)
Weighted Avg Shares4.1M4.17M4.33M10.92M13.32M
Weighted Avg Shares (Diluted)4.1M4.17M4.33M10.92M13.32M

Corbus Pharmaceuticals Holdings, Inc.

NASDAQ:CRBP

Intrinsic Alpha fair value

Locked

Current Price

$2.75

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.